カテゴリ： GlobalData, アメリカ, 企業調査

MiMedx Group Inc (MDXG)-医療機器分野：企業M&A・提携分析

◆英語タイトル：MiMedx Group Inc (MDXG) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8011154
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月21日
◆ページ数：84
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
MiMedx Group Inc (MiMedx) is a provider of bioactive healing products for tissue regeneration. The company’s products are used in the therapeutic areas of chronic wounds, dental, ophthalmology, spine, orthopedic surgery, sports medicine and urology. Its products help in reducing inflammation and scar tissue formation; enhance soft tissue healing. MiMedx’s product delivers human extracellular matrix components for regeneration of damaged or diseased tissues. The company also employs proprietary PURION Process for safe and gentle separation of the placental tissues for preserving the elements associated with healing. It offers products for membrane sub-segments such as ocular, dental, and spine. MiMedx is headquartered in Marietta, Georgia, the US.

MiMedx Group Inc (MDXG) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MiMedx Group Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
MiMedx Group Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
MiMedx Group Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
MiMedx Group Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
MiMedx Group Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
MiMedx Group Inc, Medical Equipment, Deal Details 11
Partnerships 11
MiMedx Enters Into Distribution Agreement With Medtronic And SpinalGraft Technologies 11
MiMedx Enters Into Distribution Agreement With Systagenix Wound Management For EpiFix 12
Equity Offering 13
MiMedx Completes Public Offering Of Shares For US$39 Million 13
MiMedx Group Completes Private Placement Of Shares For US$5 Million Upon Exercise Of Warrants 15
MiMedx Group Completes Private Placement Of US$6.6 Million 16
Acquisition 17
MiMedx Sells its Stability Biologics 17
MiMedx Acquires Stability Biologics 18
MiMedx Completes Acquisition Of Surgical Biologics 19
MiMedx Group Inc – Key Competitors 20
MiMedx Group Inc – Key Employees 21
MiMedx Group Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Oct 26, 2017: MiMedx Announces Record Results For Third Quarter Of 2017 And Raises Full Year Revenue Guidance 23
Oct 10, 2017: MiMedx Announces Third Quarter Revenues Of $84.6 Million Exceeds Guidance By More Than 5 Percent 26
Jul 26, 2017: MiMedx Announces Record Results For The Second Quarter Of 2017 And Raises Full Year Revenue Guidance 28
Jul 13, 2017: MiMedx Announces that its Second Quarter Revenue Exceeds the Guidance Range 31
Apr 28, 2017: MiMedx Announces Record Results For First Quarter Of 2017 32
Apr 13, 2017: MiMedx Announces First Quarter 2017 Revenue to Exceed High End of Guidance 34
Feb 23, 2017: MiMedx Announces 2016 Record Results 35
Jan 09, 2017: MiMedx Fourth Quarter 2016 Revenue in Upper Range of Guidance 37
Dec 16, 2016: MiMedx 2017 Guidance Forecasts Revenue Growth In Excess Of 21% And Operating Earnings Growth In Excess Of 90% 39
Oct 27, 2016: MiMedx Announces Third Quarter 2016 Results 41
Oct 10, 2016: MiMedx Third Quarter 2016 Revenue Exceeds Upper End of Guidance 44
Jul 26, 2016: MiMedx Announces Second Quarter 2016 Results 45
Jul 11, 2016: MiMedx Second Quarter Of 2016 Revenue Exceeds Upper End Of Guidance Range 48
Apr 25, 2016: MiMedx Announces First Quarter 2016 Results 49
Apr 10, 2016: MiMedx Announces First Quarter of 2016 Revenue Results 51
Feb 23, 2016: MiMedx Announces 2015 Record Results 52
Corporate Communications 54
Oct 03, 2017: Dr. Gloria Matthews Joins MiMedx As Its Senior Vice President Of Research And Development 54
Mar 19, 2017: MiMedx Announces The Addition Of Luis A. Aguilar To Its Board Of Directors 55
Jul 07, 2016: MiMedx Adds New Executive 56
Legal and Regulatory 57
Nov 01, 2017: MiMedx Agrees To Lawsuit Settlement With Halo Wound Solutions 57
Oct 04, 2017: MiMedx Files Lawsuit Related To Short Seller Attacks 58
Oct 02, 2017: Court Sets the Trial Date for MiMedx Patent Infringement Lawsuit Against MTF, Medline and Liventa 59
Sep 21, 2017: MiMedx Files Lawsuit Against The Capitol Forum 60
Sep 18, 2017: MiMedx Patent Infringement Lawsuit Updates 61
Jun 21, 2016: MiMedx Reaches Settlement With Medline Industries And Liventa Bioscience For Certain Claims 62
May 17, 2016: MiMedx Files Lawsuit Against Osiris For False And Misleading Representations 63
Jan 06, 2016: MiMedx Receives Certificate From FDA Allowing The Export Of MiMedx Allografts 64
Government and Public Interest 65
Jun 15, 2017: Scientific And Clinical Review Confirms Potential Of MiMedx dHACM Allografts For Regenerative Applications In Orthopedics 65
Sep 15, 2016: MiMedx Urges FDA To Reconsider Draft Guidances During Hearing 67
Product News 69
Oct 18, 2017: New Clinical Evidence And A Landmark VLU Study To Be Presented At SAWC Fall Meeting 69
Apr 05, 2017: The Use Of MiMedx Allografts From The Company’s Multiple Product Families To Be Presented At SAWC Conference 71
Feb 07, 2017: Benefits Of MiMedx dHACM Allograft Chronicled In Multiple Articles In February 2017 Supplement Edition Of Annals of Plastic Surgery 72
Jan 24, 2017: Scientific Study Confirms MiMedx dHACM Allograft Promotes Cardiac Repair Following Myocardial Infarction 74
Nov 03, 2016: MiMedx Announces USP-NF Monograph For dHACM Allografts Has Published 75
Oct 06, 2016: Advances In Regenerative Medicine With MiMedx EpiFix And AmnioFix To Be Presented At SAWC Fall Meeting 76
Sep 12, 2016: Scientific Study Confirms How MiMedx dHACM Allografts Effectively Promote Wound Repair 78
Other Significant Developments 80
Sep 13, 2017: MiMedx Reiterates Its Third Quarter Revenue Expectation To Exceed $80 Million Despite Hurricane Irma 80
Aug 09, 2017: MiMedx Hits Milestone of One Million Allografts Distributed 81
Jul 05, 2017: MiMedx Agreement With AvKARE Expires As Planned Following Completion Of Contract Wind-Down 82
Sep 06, 2016: MiMedx Reaffirms Q3 and Full Year 2016 Guidance 83
Appendix 84
Methodology 84
About GlobalData 84
Contact Us 84
Disclaimer 84

List of Tables
MiMedx Group Inc, Medical Equipment, Key Facts, 2016 2
MiMedx Group Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
MiMedx Group Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
MiMedx Group Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
MiMedx Group Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
MiMedx Group Inc, Deals By Market, 2011 to YTD 2017 9
MiMedx Group Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
MiMedx Enters Into Distribution Agreement With Medtronic And SpinalGraft Technologies 11
MiMedx Enters Into Distribution Agreement With Systagenix Wound Management For EpiFix 12
MiMedx Completes Public Offering Of Shares For US$39 Million 13
MiMedx Group Completes Private Placement Of Shares For US$5 Million Upon Exercise Of Warrants 15
MiMedx Group Completes Private Placement Of US$6.6 Million 16
MiMedx Sells its Stability Biologics 17
MiMedx Acquires Stability Biologics 18
MiMedx Completes Acquisition Of Surgical Biologics 19
MiMedx Group Inc, Key Competitors 20
MiMedx Group Inc, Key Employees 21
MiMedx Group Inc, Subsidiaries 22

★海外企業調査レポート[MiMedx Group Inc (MDXG)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Vancive Medical Technologies：医療機器：M&Aディール及び事業提携情報
    Summary Vancive Medical Technologies (Vancive) is a medical technology company with expertise in adhesive chemistries and medical technologies focused on pressure-sensitive adhesives for medical applications. The company provides product portfolio such as medical adhesive tapes, negative pressure wo …
  • Canon Inc.：企業の戦略・SWOT・財務情報
    Canon Inc. - Strategy, SWOT and Corporate Finance Report Summary Canon Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Hyduke Energy Services Inc (HYD)-石油・ガス分野：企業M&A・提携分析
    Summary Hyduke Energy Services Inc. (Hyduke) is an integrated oilfield services company that manufacture, repair and distributes oilfield equipment and supplies. It carries out the engineering, design and manufacture of land-based drilling rigs, service rigs, coiled tubing units, pump units, cranes, …
  • Mitsubishi Estate Co., Ltd.：企業の戦略・SWOT・財務分析
    Mitsubishi Estate Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Estate Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Inpex Corp (1605)：企業の財務・戦略的SWOT分析
    Inpex Corp (1605) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Aeglea BioTherapeutics Inc (AGLE)：企業の財務・戦略的SWOT分析
    Summary Aeglea BioTherapeutics Inc (Aeglea), formerly Aeglea BioTherapeutics Holdings, LLC is a biotechnology company. The company develops and commercializes human enzymes for the treatment of cancer and rare genetic diseases. The company’s lead product pipeline includes pegzilarginase (AEB1102), i …
  • CVS Health Corp (CVS)：企業の財務・戦略的SWOT分析
    CVS Health Corp (CVS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Technogenetics srl-医療機器分野：企業M&A・提携分析
    Summary Technogenetics srl (Technogenetics), a subsidiary of Shanghai Kehua Bio-engineering Co Ltd, is a biotechnology company that offers reagents in the field of biotechnology and pharmacology. The company provides immunodiagnostics products in the areas of infectious disease, and autoimmunity. It …
  • International Consolidated Airlines Group, S.A.：戦略・SWOT・企業財務分析
    International Consolidated Airlines Group, S.A. - Strategy, SWOT and Corporate Finance Report Summary International Consolidated Airlines Group, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • Vitasoy International Holdings Ltd.：企業の戦略・SWOT・財務分析
    Vitasoy International Holdings Ltd. - Strategy, SWOT and Corporate Finance Report Summary Vitasoy International Holdings Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Transnet SOC Ltd：企業の戦略的SWOT分析
    Transnet SOC Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Intellipharmaceutics International Inc (IPCI)：製薬・医療：M&Aディール及び事業提携情報
    Summary Intellipharmaceutics International Inc (Intellipharmaceutics) is a pharmaceutical company that researches, develops, manufactures, and commercializes novel and generic targeted oral solid dosage pharmaceuticals. The company develops its controlled-release and targeted-release oral solid dosa …
  • GeNeuro SA (GNRO)：企業の財務・戦略的SWOT分析
    Summary GeNeuro SA (GeNeuro) is a clinical stage pharmaceutical company that manufactures therapeutic product pipeline for disorders of the nervous system. The company provides treatments against inflammatory and degenerative disorders associated with endogenous retroviruses. GeNeuro develops therap …
  • PhaseBio Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary PhaseBio Pharmaceuticals Inc (PhaseBio) is a clinical-stage biopharmaceutical company that develops biotherapeutics for the treatment of orphan diseases and cardiopulmonary indications. The company offers ELP biopolymer technology, which includes PE0139 and PB1023 pipeline products. PhaseBio …
  • Outokumpu Oyj：戦略・SWOT・企業財務分析
    Outokumpu Oyj - Strategy, SWOT and Corporate Finance Report Summary Outokumpu Oyj - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Tullow Oil Plc (TLW)：企業の財務・戦略的SWOT分析
    Tullow Oil Plc (TLW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • JBCC Holdings Inc (9889)：企業の戦略的SWOT分析
    JBCC Holdings Inc (9889) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Gold Fields Ltd：戦略・SWOT・企業財務分析
    Gold Fields Ltd - Strategy, SWOT and Corporate Finance Report Summary Gold Fields Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Byotrol Plc (BYOT)：企業の財務・戦略的SWOT分析
    Summary Byotrol Plc (Byotrol) is a developer of residual antimicrobial technologies. The company offers multi pet surface disinfectant, advance moisture shampoo, advanced moisture, conditioning spray, advanced stain and odour, every day odour control spray, among others. It also identifies, develops …
  • Franz Haniel & Cie. GmbH：企業の戦略的SWOT分析
    Franz Haniel & Cie. GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆